Aurora Cannabis Posts Record Revenue and EBITDA on Medical Cannabis Growth
Event summary
- Aurora Cannabis reported record annual revenue of $288.6 million, up 18% YoY, driven by double-digit growth in Europe.
- Adjusted EBITDA reached $53.8 million, a 32% YoY increase, marking the company's strongest financial performance to date.
- Acquired Safari Flower Company for $26.5 million, adding a 59,000 square foot EU-GMP certified facility to its supply network.
- Divested 50.1% ownership in Bevo Agtech Inc., exiting the plant propagation business to focus on medical cannabis.
- Maintains a strong balance sheet with $164.7 million in cash and no debt.
The big picture
Aurora Cannabis is doubling down on its medical cannabis strategy, exiting lower-margin consumer and plant propagation businesses to focus on international markets. The company's record financial performance underscores the profitability of its medical cannabis operations, particularly in Europe. However, it must navigate margin pressures in Canada and efficiently integrate its latest acquisition to maintain growth.
What we're watching
- International Growth
- Whether Aurora can sustain its momentum in Europe, particularly in Germany and Poland, amid evolving market dynamics.
- Margin Pressures
- How the company will offset margin reductions in the Canadian medical business following government reimbursement pricing changes.
- Operational Efficiency
- The pace at which Aurora integrates Safari Flower Company and expands EU-GMP capacity to support international growth.
Related topics